Skip to content
Screener

Investing Cash Flow at other companies

Pfizer logo
PfizerPFE
$785M-76.0%
Cardinal Health logo
Cardinal HealthCAH
-$181M+93.8%
McKesson logo
McKessonMCK
-$214M+94.0%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$3.05M+55.8%
Cencora logo
CencoraCOR
-$240.15M-2.3%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$123.1M+173%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Acquisition of intangible assets(85,000)(5,100)
Deposits for future acquisition of property, plant and equipment(20,580)(4,632)
Proceeds from sale of property, plant and equipment1,379
Net cash used in investing activities(144,452)(44,345)
Cash flows from financing activities:
Payments of principal on debt, revolving credit facilities, financing leases and other(147,027)(251,076)
Proceeds from issuance of debt134,673
Payments of deferred financing and refinancing costs(1,982)(1,745)

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s investing cash flow?
Amneal Pharmaceuticals, Inc. (AMRX) reported investing cash flow of -$122.74M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s investing cash flow changed year-over-year?
Amneal Pharmaceuticals, Inc.'s investing cash flow decreased by 362.4% year-over-year, from -$26.55M to -$122.74M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s investing cash flow?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s investing cash flow has grown at a -12.8% compound annual growth rate (CAGR), from -$194.18M to -$112.26M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Amneal Pharmaceuticals, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude